Visceral Pain - Pipeline Review, H2 2018
Visceral Pain - Pipeline Review, H2 2018
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2018, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape.
Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pain modifiers such as tricyclic antidepressants or anticonvulsants.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Visceral Pain - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Visceral Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 6 molecules, respectively.
Visceral Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2018, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape.
Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pain modifiers such as tricyclic antidepressants or anticonvulsants.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Visceral Pain - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Visceral Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 6 molecules, respectively.
Visceral Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Visceral Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Visceral Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Visceral Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Visceral Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Visceral Pain (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Visceral Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Visceral Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Visceral Pain - Overview
Visceral Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Visceral Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Visceral Pain - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Anavex Life Sciences Corp
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Astellas Pharma Inc
Cadila Healthcare Ltd
Chromocell Corp
Echo Pharmaceuticals BV
Eisai Co Ltd
Eli Lilly and Co
Grunenthal GmbH
Idera Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Pfizer Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Visceral Pain - Drug Profiles
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-1066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NLRP3 for Interstitial Cystitis and Uveitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ART-26.12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-8464 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-2508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HS-665 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICE-3682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-6860 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olorinab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPA1 for Acute Pani and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZH-853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYKR-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Visceral Pain - Dormant Projects
Visceral Pain - Discontinued Products
Visceral Pain - Product Development Milestones
Featured News & Press Releases
May 22, 2018: Alivio Therapeutics Announces Issuance of Two U.S. Patents Broadly Covering Compositions of Matter for Inflammation-Targeting Technology Platform
Jul 13, 2017: PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology
Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain
Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
Nov 19, 2012: First patient dosed with Namisol in a Phase II trial in patients with chronic post-surgical abdominal pain
Oct 15, 2012: First patient dosed with Namisol in a second phase II study in Chronic Pancreatitis
Oct 06, 2011: First Chronic Pancreatitis patient dosed with Namisol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Visceral Pain - Overview
Visceral Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Visceral Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Visceral Pain - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Anavex Life Sciences Corp
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Astellas Pharma Inc
Cadila Healthcare Ltd
Chromocell Corp
Echo Pharmaceuticals BV
Eisai Co Ltd
Eli Lilly and Co
Grunenthal GmbH
Idera Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Pfizer Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Visceral Pain - Drug Profiles
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-1066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NLRP3 for Interstitial Cystitis and Uveitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ART-26.12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-8464 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-2508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HS-665 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICE-3682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-6860 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olorinab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPA1 for Acute Pani and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZH-853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYKR-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Visceral Pain - Dormant Projects
Visceral Pain - Discontinued Products
Visceral Pain - Product Development Milestones
Featured News & Press Releases
May 22, 2018: Alivio Therapeutics Announces Issuance of Two U.S. Patents Broadly Covering Compositions of Matter for Inflammation-Targeting Technology Platform
Jul 13, 2017: PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology
Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain
Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
Nov 19, 2012: First patient dosed with Namisol in a Phase II trial in patients with chronic post-surgical abdominal pain
Oct 15, 2012: First patient dosed with Namisol in a second phase II study in Chronic Pancreatitis
Oct 06, 2011: First Chronic Pancreatitis patient dosed with Namisol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Visceral Pain, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2018
Visceral Pain - Pipeline by Anavex Life Sciences Corp, H2 2018
Visceral Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Artelo Biosciences Inc, H2 2018
Visceral Pain - Pipeline by Astellas Pharma Inc, H2 2018
Visceral Pain - Pipeline by Cadila Healthcare Ltd, H2 2018
Visceral Pain - Pipeline by Chromocell Corp, H2 2018
Visceral Pain - Pipeline by Echo Pharmaceuticals BV, H2 2018
Visceral Pain - Pipeline by Eisai Co Ltd, H2 2018
Visceral Pain - Pipeline by Eli Lilly and Co, H2 2018
Visceral Pain - Pipeline by Grunenthal GmbH, H2 2018
Visceral Pain - Pipeline by Idera Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Visceral Pain - Pipeline by Kytogenics Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Lipella Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Pfizer Inc, H2 2018
Visceral Pain - Pipeline by UCB SA, H2 2018
Visceral Pain - Pipeline by Urigen Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Xigen SA, H2 2018
Visceral Pain - Dormant Projects, H2 2018
Visceral Pain - Dormant Projects, H2 2018 (Contd.1), H2 2018
Visceral Pain - Dormant Projects, H2 2018 (Contd.2), H2 2018
Visceral Pain - Dormant Projects, H2 2018 (Contd.3), H2 2018
Visceral Pain - Discontinued Products, H2 2018
Number of Products under Development for Visceral Pain, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2018
Visceral Pain - Pipeline by Anavex Life Sciences Corp, H2 2018
Visceral Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Artelo Biosciences Inc, H2 2018
Visceral Pain - Pipeline by Astellas Pharma Inc, H2 2018
Visceral Pain - Pipeline by Cadila Healthcare Ltd, H2 2018
Visceral Pain - Pipeline by Chromocell Corp, H2 2018
Visceral Pain - Pipeline by Echo Pharmaceuticals BV, H2 2018
Visceral Pain - Pipeline by Eisai Co Ltd, H2 2018
Visceral Pain - Pipeline by Eli Lilly and Co, H2 2018
Visceral Pain - Pipeline by Grunenthal GmbH, H2 2018
Visceral Pain - Pipeline by Idera Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Visceral Pain - Pipeline by Kytogenics Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Lipella Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Pfizer Inc, H2 2018
Visceral Pain - Pipeline by UCB SA, H2 2018
Visceral Pain - Pipeline by Urigen Pharmaceuticals Inc, H2 2018
Visceral Pain - Pipeline by Xigen SA, H2 2018
Visceral Pain - Dormant Projects, H2 2018
Visceral Pain - Dormant Projects, H2 2018 (Contd.1), H2 2018
Visceral Pain - Dormant Projects, H2 2018 (Contd.2), H2 2018
Visceral Pain - Dormant Projects, H2 2018 (Contd.3), H2 2018
Visceral Pain - Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development for Visceral Pain, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Addex Therapeutics Ltd
Anavex Life Sciences Corp
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Astellas Pharma Inc
Cadila Healthcare Ltd
Chromocell Corp
Echo Pharmaceuticals BV
Eisai Co Ltd
Eli Lilly and Co
Grunenthal GmbH
Idera Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Pfizer Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Number of Products under Development for Visceral Pain, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Addex Therapeutics Ltd
Anavex Life Sciences Corp
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Astellas Pharma Inc
Cadila Healthcare Ltd
Chromocell Corp
Echo Pharmaceuticals BV
Eisai Co Ltd
Eli Lilly and Co
Grunenthal GmbH
Idera Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Pfizer Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
